Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing
Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing
Publish Date: 2026-05-07 07:00:00
Source Domain: www.pharmaceutical-technology.com
Eli Lilly is expanding its presence within its home state of Indiana with a $4.5bn pledge to its Lebanon campus. Credit: rarrarorro / Shutterstock.com.
Eli Lilly has shared plans to invest a further $4.5bn into its manufacturing presence in Indiana, taking the pharma company’s total investment into the state to $21bn since 2020.
Through this commitment, Lilly will expand operations across two of the three sites on its Lebanon campus – including the company’s active pharmaceutical ingredient (API) production facility and its dedicated genetic medicines manufacturing centre, which opened on 6 May.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
The API facility, which currently produces Lilly’s best-selling tirzepatide franchise, will now be tailored to manufacture the company’s newly approved oral weight loss drug, Foundayo (orforglipron), which is currently in the throes of its US launch. Prior to Foundayo’s market debut, Lilly made several manufacturing investments in the US, China and Europe to keep up with potential demand for the drug, while opting to create a stockpile to further diminish the risk of shortages.
Alongside Foundayo production, Lilly’s API facility will also manufacture the active ingredient in its “triple-G” agonist, retatrutide, which is currently in late-stage trials for obesity and type 2…
